logo-loader
viewMedexus Pharmaceuticals Inc

Full interview: Medexus Pharmaceuticals ensuring its prescription drug supply chain remains solid

Medexus Pharmaceuticals Inc (CVE:MDP) (OTCMKTS:PDDPF) CEO Ken d’Entremont tells Proactive its business remains strong in the face of the coronavirus outbreak.

d’Entremont says the pharmaceutical company is ensuring its supply chain remains 'solid' and is sitting on 3-6 months of prescription drug inventory.

Quick facts: Medexus Pharmaceuticals Inc

Price: 2.2 CAD

TSX-V:MDP
Market: TSX-V
Market Cap: $30.93 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Medexus Pharmaceuticals Inc named herein, including the promotion by the Company of Medexus Pharmaceuticals Inc in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Medexus Expands US assets by acquiring Aptevo Bio Therapeutics

Medexus Pharmaceuticals (CVE: MDP-OTCQB: PDDPF) CEO Ken d’Entremont joined Proactive's Steve Darling in Toronto with news the company has acquired Aptevo BioTherapeutics LLC, which owns the worldwide rights to the commercial hematology asset, IXINITY, for up-front cash consideration of...

3 weeks, 6 days ago

2 min read